Clinical Trials Browser

INDUSTRY × Recurrence × Dexamethasone × Clear all

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Recurrence, Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Clinical Trials

SUCCESSOR-2

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

SUCCESSOR-1

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

MonumenTAL-3

STOMP

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

SELECT

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

BOSTON

ARROW2

PANORAMA_3

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

SLAM

KarMMa-3

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

STRATUS

MK-0683-095

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

MK-0683-074

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

PANORAMA-1

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

CLC-102

MACS1271

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

PANORAMA-5

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

GCS-100LE

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma